Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
VYNE Therapeutics Stock (NASDAQ: VYNE) stock price, news, charts, stock research, profile.
Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.990 | -2.820 | -0.8300 | ||||
REV | 100.000K | 135.000K | 35.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | 28.00 | 28.00 |
2023-05-12 | Cantor Fitzgerald | Louise Chen | Maintains | Overweight | Raises | 5.00 | 9.00 |
2023-05-12 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 28.00 |
2023-04-19 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | Buy | Maintains | - | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
VYNE | VYNE Therapeutics | -2.74% | 12.8M |
CING | Cingulate | -4.14% | 12M |
ITRM | Iterum Therapeutics | 15.24% | 10.4M |
COCP | Cocrystal Pharma | 5.13% | 20.9M |
ONTX | Onconova Therapeutics | 5.76% | 16M |
You can purchase shares of VYNE Therapeutics (NASDAQ: VYNE) through any online brokerage.
Other companies in VYNE Therapeutics’s space includes: Cingulate (NASDAQ:CING), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and CalciMedica (NASDAQ:CALC).
The latest price target for VYNE Therapeutics (NASDAQ: VYNE) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 28.00 expecting VYNE to rise to within 12 months (a possible 617.95% upside). 6 analyst firms have reported ratings in the last year.
The stock price for VYNE Therapeutics (NASDAQ: VYNE) is $3.9 last updated September 29, 2023 at 10:55 PM UTC.
There is no dividend information for VYNE Therapeutics.
VYNE Therapeutics’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for VYNE Therapeutics.
VYNE Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
VYNE Therapeutics Stock (NASDAQ: VYNE) stock price, news, charts, stock research, profile.
Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.990 | -2.820 | -0.8300 | ||||
REV | 100.000K | 135.000K | 35.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | 28.00 | 28.00 |
2023-05-12 | Cantor Fitzgerald | Louise Chen | Maintains | Overweight | Raises | 5.00 | 9.00 |
2023-05-12 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 28.00 |
2023-04-19 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | Buy | Maintains | - | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
VYNE | VYNE Therapeutics | -2.74% | 12.8M |
CING | Cingulate | -4.14% | 12M |
ITRM | Iterum Therapeutics | 15.24% | 10.4M |
COCP | Cocrystal Pharma | 5.13% | 20.9M |
ONTX | Onconova Therapeutics | 5.76% | 16M |
You can purchase shares of VYNE Therapeutics (NASDAQ: VYNE) through any online brokerage.
Other companies in VYNE Therapeutics’s space includes: Cingulate (NASDAQ:CING), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and CalciMedica (NASDAQ:CALC).
The latest price target for VYNE Therapeutics (NASDAQ: VYNE) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 28.00 expecting VYNE to rise to within 12 months (a possible 617.95% upside). 6 analyst firms have reported ratings in the last year.
The stock price for VYNE Therapeutics (NASDAQ: VYNE) is $3.9 last updated September 29, 2023 at 10:55 PM UTC.
There is no dividend information for VYNE Therapeutics.
VYNE Therapeutics’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for VYNE Therapeutics.
VYNE Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
VYNE Therapeutics Stock (NASDAQ: VYNE) stock price, news, charts, stock research, profile.
Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.990 | -2.820 | -0.8300 | ||||
REV | 100.000K | 135.000K | 35.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | 28.00 | 28.00 |
2023-05-12 | Cantor Fitzgerald | Louise Chen | Maintains | Overweight | Raises | 5.00 | 9.00 |
2023-05-12 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 28.00 |
2023-04-19 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | Buy | Maintains | - | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
VYNE | VYNE Therapeutics | -2.74% | 12.8M |
CING | Cingulate | -4.14% | 12M |
ITRM | Iterum Therapeutics | 15.24% | 10.4M |
COCP | Cocrystal Pharma | 5.13% | 20.9M |
ONTX | Onconova Therapeutics | 5.76% | 16M |
You can purchase shares of VYNE Therapeutics (NASDAQ: VYNE) through any online brokerage.
Other companies in VYNE Therapeutics’s space includes: Cingulate (NASDAQ:CING), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and CalciMedica (NASDAQ:CALC).
The latest price target for VYNE Therapeutics (NASDAQ: VYNE) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 28.00 expecting VYNE to rise to within 12 months (a possible 617.95% upside). 6 analyst firms have reported ratings in the last year.
The stock price for VYNE Therapeutics (NASDAQ: VYNE) is $3.9 last updated September 29, 2023 at 10:55 PM UTC.
There is no dividend information for VYNE Therapeutics.
VYNE Therapeutics’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for VYNE Therapeutics.
VYNE Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
VYNE Therapeutics Stock (NASDAQ: VYNE) stock price, news, charts, stock research, profile.
Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.990 | -2.820 | -0.8300 | ||||
REV | 100.000K | 135.000K | 35.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | 28.00 | 28.00 |
2023-05-12 | Cantor Fitzgerald | Louise Chen | Maintains | Overweight | Raises | 5.00 | 9.00 |
2023-05-12 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 28.00 |
2023-04-19 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | Buy | Maintains | - | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
VYNE | VYNE Therapeutics | -2.74% | 12.8M |
CING | Cingulate | -4.14% | 12M |
ITRM | Iterum Therapeutics | 15.24% | 10.4M |
COCP | Cocrystal Pharma | 5.13% | 20.9M |
ONTX | Onconova Therapeutics | 5.76% | 16M |
You can purchase shares of VYNE Therapeutics (NASDAQ: VYNE) through any online brokerage.
Other companies in VYNE Therapeutics’s space includes: Cingulate (NASDAQ:CING), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and CalciMedica (NASDAQ:CALC).
The latest price target for VYNE Therapeutics (NASDAQ: VYNE) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 28.00 expecting VYNE to rise to within 12 months (a possible 617.95% upside). 6 analyst firms have reported ratings in the last year.
The stock price for VYNE Therapeutics (NASDAQ: VYNE) is $3.9 last updated September 29, 2023 at 10:55 PM UTC.
There is no dividend information for VYNE Therapeutics.
VYNE Therapeutics’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for VYNE Therapeutics.
VYNE Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
VYNE Therapeutics Stock (NASDAQ: VYNE) stock price, news, charts, stock research, profile.
Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.990 | -2.820 | -0.8300 | ||||
REV | 100.000K | 135.000K | 35.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | 28.00 | 28.00 |
2023-05-12 | Cantor Fitzgerald | Louise Chen | Maintains | Overweight | Raises | 5.00 | 9.00 |
2023-05-12 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 28.00 |
2023-04-19 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | Buy | Maintains | - | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
VYNE | VYNE Therapeutics | -2.74% | 12.8M |
CING | Cingulate | -4.14% | 12M |
ITRM | Iterum Therapeutics | 15.24% | 10.4M |
COCP | Cocrystal Pharma | 5.13% | 20.9M |
ONTX | Onconova Therapeutics | 5.76% | 16M |
You can purchase shares of VYNE Therapeutics (NASDAQ: VYNE) through any online brokerage.
Other companies in VYNE Therapeutics’s space includes: Cingulate (NASDAQ:CING), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and CalciMedica (NASDAQ:CALC).
The latest price target for VYNE Therapeutics (NASDAQ: VYNE) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 28.00 expecting VYNE to rise to within 12 months (a possible 617.95% upside). 6 analyst firms have reported ratings in the last year.
The stock price for VYNE Therapeutics (NASDAQ: VYNE) is $3.9 last updated September 29, 2023 at 10:55 PM UTC.
There is no dividend information for VYNE Therapeutics.
VYNE Therapeutics’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for VYNE Therapeutics.
VYNE Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
VYNE Therapeutics Stock (NASDAQ: VYNE) stock price, news, charts, stock research, profile.
Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.990 | -2.820 | -0.8300 | ||||
REV | 100.000K | 135.000K | 35.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | 28.00 | 28.00 |
2023-05-12 | Cantor Fitzgerald | Louise Chen | Maintains | Overweight | Raises | 5.00 | 9.00 |
2023-05-12 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 28.00 |
2023-04-19 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | Buy | Maintains | - | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
VYNE | VYNE Therapeutics | -2.74% | 12.8M |
CING | Cingulate | -4.14% | 12M |
ITRM | Iterum Therapeutics | 15.24% | 10.4M |
COCP | Cocrystal Pharma | 5.13% | 20.9M |
ONTX | Onconova Therapeutics | 5.76% | 16M |
You can purchase shares of VYNE Therapeutics (NASDAQ: VYNE) through any online brokerage.
Other companies in VYNE Therapeutics’s space includes: Cingulate (NASDAQ:CING), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and CalciMedica (NASDAQ:CALC).
The latest price target for VYNE Therapeutics (NASDAQ: VYNE) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 28.00 expecting VYNE to rise to within 12 months (a possible 617.95% upside). 6 analyst firms have reported ratings in the last year.
The stock price for VYNE Therapeutics (NASDAQ: VYNE) is $3.9 last updated September 29, 2023 at 10:55 PM UTC.
There is no dividend information for VYNE Therapeutics.
VYNE Therapeutics’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for VYNE Therapeutics.
VYNE Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
VYNE Therapeutics Stock (NASDAQ: VYNE) stock price, news, charts, stock research, profile.
Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.990 | -2.820 | -0.8300 | ||||
REV | 100.000K | 135.000K | 35.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | 28.00 | 28.00 |
2023-05-12 | Cantor Fitzgerald | Louise Chen | Maintains | Overweight | Raises | 5.00 | 9.00 |
2023-05-12 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 28.00 |
2023-04-19 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | Buy | Maintains | - | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
VYNE | VYNE Therapeutics | -2.74% | 12.8M |
CING | Cingulate | -4.14% | 12M |
ITRM | Iterum Therapeutics | 15.24% | 10.4M |
COCP | Cocrystal Pharma | 5.13% | 20.9M |
ONTX | Onconova Therapeutics | 5.76% | 16M |
You can purchase shares of VYNE Therapeutics (NASDAQ: VYNE) through any online brokerage.
Other companies in VYNE Therapeutics’s space includes: Cingulate (NASDAQ:CING), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and CalciMedica (NASDAQ:CALC).
The latest price target for VYNE Therapeutics (NASDAQ: VYNE) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 28.00 expecting VYNE to rise to within 12 months (a possible 617.95% upside). 6 analyst firms have reported ratings in the last year.
The stock price for VYNE Therapeutics (NASDAQ: VYNE) is $3.9 last updated September 29, 2023 at 10:55 PM UTC.
There is no dividend information for VYNE Therapeutics.
VYNE Therapeutics’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for VYNE Therapeutics.
VYNE Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
VYNE Therapeutics Stock (NASDAQ: VYNE) stock price, news, charts, stock research, profile.
Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.990 | -2.820 | -0.8300 | ||||
REV | 100.000K | 135.000K | 35.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | 28.00 | 28.00 |
2023-05-12 | Cantor Fitzgerald | Louise Chen | Maintains | Overweight | Raises | 5.00 | 9.00 |
2023-05-12 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 28.00 |
2023-04-19 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | Buy | Maintains | - | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
VYNE | VYNE Therapeutics | -2.74% | 12.8M |
CING | Cingulate | -4.14% | 12M |
ITRM | Iterum Therapeutics | 15.24% | 10.4M |
COCP | Cocrystal Pharma | 5.13% | 20.9M |
ONTX | Onconova Therapeutics | 5.76% | 16M |
You can purchase shares of VYNE Therapeutics (NASDAQ: VYNE) through any online brokerage.
Other companies in VYNE Therapeutics’s space includes: Cingulate (NASDAQ:CING), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and CalciMedica (NASDAQ:CALC).
The latest price target for VYNE Therapeutics (NASDAQ: VYNE) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 28.00 expecting VYNE to rise to within 12 months (a possible 617.95% upside). 6 analyst firms have reported ratings in the last year.
The stock price for VYNE Therapeutics (NASDAQ: VYNE) is $3.9 last updated September 29, 2023 at 10:55 PM UTC.
There is no dividend information for VYNE Therapeutics.
VYNE Therapeutics’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for VYNE Therapeutics.
VYNE Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
VYNE Therapeutics Stock (NASDAQ: VYNE) stock price, news, charts, stock research, profile.
Open4.150 | Close4.040 |
Vol / Avg.11.525K / 15.621K | Mkt Cap12.792M |
Day Range3.920 - 4.293 | 52 Wk Range2.034 - 8.730 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.990 | -2.820 | -0.8300 | ||||
REV | 100.000K | 135.000K | 35.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | 28.00 | 28.00 |
2023-05-12 | Cantor Fitzgerald | Louise Chen | Maintains | Overweight | Raises | 5.00 | 9.00 |
2023-05-12 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 28.00 |
2023-04-19 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | Buy | Maintains | - | 28.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
VYNE | VYNE Therapeutics | -2.74% | 12.8M |
CING | Cingulate | -4.14% | 12M |
ITRM | Iterum Therapeutics | 15.24% | 10.4M |
COCP | Cocrystal Pharma | 5.13% | 20.9M |
ONTX | Onconova Therapeutics | 5.76% | 16M |
You can purchase shares of VYNE Therapeutics (NASDAQ: VYNE) through any online brokerage.
Other companies in VYNE Therapeutics’s space includes: Cingulate (NASDAQ:CING), Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX) and CalciMedica (NASDAQ:CALC).
The latest price target for VYNE Therapeutics (NASDAQ: VYNE) was reported by HC Wainwright & Co. on Monday, August 14, 2023. The analyst firm set a price target for 28.00 expecting VYNE to rise to within 12 months (a possible 617.95% upside). 6 analyst firms have reported ratings in the last year.
The stock price for VYNE Therapeutics (NASDAQ: VYNE) is $3.9 last updated September 29, 2023 at 10:55 PM UTC.
There is no dividend information for VYNE Therapeutics.
VYNE Therapeutics’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for VYNE Therapeutics.
VYNE Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.